PepGen (PEPG) Q2 Loss Narrows 19.5%
PepGen (NASDAQ:PEPG), a biotechnology company focused on developing oligonucleotide-based therapies for neuromuscular diseases, released its earnings for the second quarter of 2025 on August 7, 2025. The biggest news was a GAAP net loss per share of $(0.70), which was better than the estimated $(0.85) GAAP loss expected by analysts. This performance was aided by reduced research and development expenses. As PepGen is still pre-commercial, no revenue was reported or expected. The period showed ongoing clinical progress, a narrowing loss, and careful cash management. However, cash reserves decreased, shortening the runway into the second quarter of 2026.
Source: Analyst estimates for the quarter provided by FactSet.
PepGen develops new therapies for genetic neuromuscular diseases using its Enhanced Delivery Oligonucleotide (EDO) platform. This technology is designed to improve the delivery of oligonucleotide drugs, which are short strands of genetic material, into muscle cells. Its main programs target myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), two inherited disorders that cause muscle weakness and deterioration.
Source Fool.com
